JAN 9 2027
Mineralys Therapeutics — lorundrostat $MLYS
for uncontrolled hypertension (add-on therapy)
Accepted MAR 9 2026.
for uncontrolled hypertension (add-on therapy)
Accepted MAR 9 2026.
Uncontrolled hypertension is persistently high blood pressure that raises the risk of heart attack, stroke, and kidney disease despite medication. Lorundrostat is an oral drug that selectively blocks the enzyme aldosterone synthase, which the body uses to produce the hormone aldosterone. By reducing aldosterone levels, the drug may help lower blood pressure in people whose condition is not managed by other therapies.
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.
Source: ClinicalTrials.gov